Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jun;23(5):337-51.
doi: 10.1089/cap.2012.0096.

Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms

Deborah A Pearson  1 , Cynthia W Santos, Michael G Aman, L Eugene Arnold, Charles D Casat, Rosleen Mansour, David M Lane, Katherine A Loveland, Oscar G Bukstein, Susan W Jerger, Perry Factor, Salome Vanwoerden, Evelyn Perez, Lynne A Cleveland
Affiliations
Randomized Controlled Trial

Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms

Deborah A Pearson et al. J Child Adolesc Psychopharmacol. 2013 Jun.

Abstract

Objective: The purpose of this study was to examine the behavioral effects of four doses of psychostimulant medication, combining extended-release methylphenidate (MPH) in the morning with immediate-release MPH in the afternoon.

Method: The sample comprised 24 children (19 boys; 5 girls) who met American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR) criteria for an autism spectrum disorder (ASD) on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS), and had significant symptoms of attention-deficit/hyperactivity disorder (ADHD). This sample consisted of elementary school-age, community-based children (mean chronological age=8.8 years, SD=1.7; mean intelligence quotient [IQ]=85; SD=16.8). Effects of four dose levels of MPH on parent and teacher behavioral ratings were investigated using a within-subject, crossover, placebo-controlled design.

Results: MPH treatment was associated with significant declines in hyperactive and impulsive behavior at both home and school. Parents noted significant declines in inattentive and oppositional behavior, and improvements in social skills. No exacerbation of stereotypies was noted, and side effects were similar to those seen in typically developing children with ADHD. Dose response was primarily linear in the dose range studied.

Conclusions: The results of this study suggest that MPH formulations are efficacious and well-tolerated for children with ASD and significant ADHD symptoms.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Study recruitment and retention.
FIG. 2.
FIG. 2.
Parent behavioral ratings on the Conners' Parent Rating Scale-Revised (CPRS-R) as a function of methylphenidate dose in children with autism spectrum disorders (ASD) and symptoms of attention-deficit/hyperactivity disorder (ADHD).
FIG. 3.
FIG. 3.
Teacher behavioral ratings on the Conners' Teacher Rating Scale-Revised (CTRS-R) as a function of methylphenidate dose in children with autism spectrum disorders (ASD) and symptoms of attention-deficit/hyperactivity disorder (ADHD).
See this image and copyright information in PMC

References

    1. Aman MG. Stimulant drug effects in developmental disorders and hyperactivity: Toward a resolution of disparate findings. J Autism Dev Disord. 1982;12:385–398. - PubMed
    1. Aman MG. Stimulant drugs in the developmental disabilities revisited. J Dev Physical Disabilities. 1996;8:347–365.
    1. Aman MG. Buican B. Arnold LE. Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies. J Child Adolesc Psychopharmacol. 2003;13:29–40. - PubMed
    1. Aman MG. DeSmedt G. Derivan A. Lyons B. Findling RL. Hagerman R. Handen B. Hellings J. Lesem M. Pahl J. Pearson DA. Rieser M. Singh NN. Swanson J. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337–1346. - PubMed
    1. Aman MG. Lam KSL. Van Bourgondien ME. Medication patterns in patients with autism: Temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol. 2005;15:116–126. - PubMed

Publication types

MeSH terms

Substances